Literature DB >> 12234857

Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Amar Safdar1, Vishnu Chaturvedi, Brian S Koll, Davise H Larone, David S Perlin, Donald Armstrong.   

Abstract

Since the 1990s, the substantial increase in the rate of Candida glabrata infections has become a serious problem. As most C. glabrata infections arise from the host's endogenous microflora, the present prospective, multicenter analysis included all clinical isolates associated with colonization and with systemic and hematogenous candidiasis. Among 347 C. glabrata isolates, the overall rates of resistance to fluconazole (MIC > or = 64 micro g/ml) and itraconazole (MIC > or = 1 micro g/ml) were 10.7 and 15.2%, respectively, although for half (n = 148) of the itraconazole-susceptible isolates the MICs (0.25 to 0.5 micro g/ml) were in the susceptible-dependent upon dose range. Fluconazole resistance was more common among C. glabrata isolates obtained from centers caring for patients with cancer (MICs at which 90% of isolates are inhibited [MIC(90)s] = 32 micro g/ml) or AIDS (MIC(90)s > 64 micro g/ml) than among C. glabrata isolates from a community-based university medical center (MIC(90)s = 16 micro g/ml) (P = 0.001). Thirty-three bloodstream isolates and those obtained from other body sites had similar in vitro susceptibility profiles. The fluconazole MIC(90)s (< or =16 micro g/ml) for C. glabrata yeast isolates from the gastrointestinal tract were lower than those (> or =64 micro g/ml) for C. glabrata isolates from respiratory and urinary tract samples (P = 0.01). A similar discrepancy for itraconazole was not significant (P > 0.5). We did not observe differences in fluconazole or itraconazole susceptibility profiles among C. glabrata isolates associated with either hematogenous dissemination or colonization. The significant discrepancy in antifungal susceptibility among C. glabrata organisms isolated from hospitals in the same geographic region emphasizes the significance of periodic susceptibility surveillance programs for individual institutions, especially those providing care to patients at risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234857      PMCID: PMC128796          DOI: 10.1128/AAC.46.10.3268-3272.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies.

Authors:  A Safdar; D Armstrong
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

2.  [Susceptibility to fluconazole and itraconazole in isolates of Candida spp. from HIV-positive and HIV-negative patients].

Authors:  S Bernal; M J Gutiérrez; M C Serrano; M Chávez; A Valverde; G Quindós; E M Mazuelos
Journal:  Rev Esp Quimioter       Date:  2000-03       Impact factor: 1.553

3.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

4.  Fungemia in HIV-infected patients: a 12-year study in a tertiary care hospital.

Authors:  J Garbino; L Kolarova; D Lew; B Hirschel; P Rohner
Journal:  AIDS Patient Care STDS       Date:  2001-08       Impact factor: 5.078

Review 5.  Infectious morbidity in critically ill patients with cancer.

Authors:  A Safdar; D Armstrong
Journal:  Crit Care Clin       Date:  2001-07       Impact factor: 3.598

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

8.  Prospective epidemiologic analysis of triazole-resistant nosocomial Candida glabrata isolated from patients at a comprehensive cancer center.

Authors:  Amar Safdar; Donald Armstrong; Emily W Cross; David S Perlin
Journal:  Int J Infect Dis       Date:  2002-09       Impact factor: 3.623

9.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

10.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more
  11 in total

1.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Biographical Feature: Davise H. Larone, Ph.D.

Authors:  Karen C Carroll
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

4.  Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Barbara Fiori; Stefania Ranno; Riccardo Torelli; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  CHROMagar Candida as the sole primary medium for isolation of yeasts and as a source medium for the rapid-assimilation-of-trehalose test.

Authors:  Melissa P Murray; Riva Zinchuk; Davise H Larone
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

6.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

7.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers.

Authors:  Satoshi Sobue; Keith Tan; Gary Layton; Malcolm Eve; J Brian Sanderson
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

9.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Characteristics of infective endocarditis in a cancer population.

Authors:  Cullen Grable; Syed W Yusuf; Juhee Song; George M Viola; Owais Ulhaq; Jose Banchs; Corey T Jensen; Harsh Goel; Saamir A Hassan
Journal:  Open Heart       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.